Quantcast

Latest eFlow Technology Stories

2011-04-08 10:00:00

DENVER, April 8, 2011 /PRNewswire/ -- A state-of-the-art, eFlow Technology nebulizer (PARI Pharma GmbH) has lifted one Denver Zoo orangutan's health and spirits. Mias (Mee-us), a 27-year-old orangutan, has what veterinarians believe to be chronic airsacculitis, a complex respiratory disease that is a substantial problem in both wild and zoo orangutans. Current information suggests that this condition in orangutans may also have some similarities to cystic fibrosis in people. (Photo:...

2010-02-23 10:22:00

MONTEREY, Calif., Feb. 23 /PRNewswire/ -- Altera, which uses eFlow Technology, was cleared to market today by the FDA as the first drug-specific nebulizer for use in the treatment of patients with cystic fibrosis and has been specifically developed to deliver Gilead Sciences' Cayston (aztreonam for inhalation solution) 75 mg. Cayston is a new inhaled antibiotic that received marketing approval from the U.S. Food and Drug Administration (FDA) yesterday as a treatment to improve respiratory...

2009-09-23 12:27:00

MONTEREY, Calif., Sept. 23 /PRNewswire/ -- PARI Pharma's Altera, which uses eFlow Technology, is the first drug-specific nebuliser for cystic fibrosis and has been specifically developed to deliver Gilead Sciences' Cayston. Cayston, aztreonam lysine 75 mg powder and solvent for nebuliser solution, is a new antibiotic that received conditional marketing approval from the European Commission as a suppressive therapy for cystic fibrosis patients, 18 years and older, who have chronic...

2009-09-14 12:42:00

MONTEREY, Calif., Sept. 14 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. reported positive top line results from a Phase 2b clinical trial with Aeroquin, a novel aerosol formulation of levofloxacin delivered by an optimized Investigational eFlow Nebulizer System from PARI Pharma. In the Mpex cystic fibrosis trial, nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa in sputum after 28 days of dosing versus placebo. "It is exciting to see these...

2009-09-14 07:00:00

MONMOUTH JUNCTION, N.J., Sept. 14 /PRNewswire/ -- Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas...

2009-05-20 14:26:00

Positive Results Based on New DSCG Formulation & eFlow Technology Delivery MUNICH and MONTEREY, Calif., May 20 /PRNewswire/ -- This week, Swiss researchers presented positive data from an ongoing Phase II clinical study at the American Thoracic Society (ATS) International Conference that compared PARI Pharma's inhaled IsoCrom, an isotonic 1% disodium cromoglycate (DSCG) solution, to inhaled corticosteroids (ICS) in 28 children with atopic asthma. Results showed decreases in mean asthma...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin